Ratings Yield10 Bioscience, Inc.

Equities

YTEN

US98585K8541

Market Closed - OTC Markets Other stock markets 01:29:56 18/05/2024 am IST			5-day change	1st Jan Change
2.11 ^USD	-10.97%		-65.07%	-63.26%

15/05	Earnings Flash (YTEN) YIELD10 BIOSCIENCE Posts Q1 Revenue $300,000	MT
15/05	Top Midday Decliners	MT

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Over the past four months, analysts' average price target has been revised downwards significantly.
Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
YIELD10 BIOSCIENCE, INC.	-63.26%	1.36M	-
IQVIA HOLDINGS INC.	-0.09%	42.12B	B
LONZA GROUP AG	+49.62%	42.05B	A
CELLTRION, INC.	-4.96%	29.18B	C
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B	B
BIO-TECHNE CORPORATION	+8.61%	13.21B	B+
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B	B+
MEDPACE HOLDINGS, INC.	+28.31%	12.16B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-6.26%	11.42B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes